152 related articles for article (PubMed ID: 29417258)
1. Impact of comorbidities at diagnosis on prostate cancer treatment and survival.
Matthes KL; Limam M; Pestoni G; Held L; Korol D; Rohrmann S
J Cancer Res Clin Oncol; 2018 Apr; 144(4):707-715. PubMed ID: 29417258
[TBL] [Abstract][Full Text] [Related]
2. The risk of prostate cancer mortality and cardiovascular mortality of nonmetastatic prostate cancer patients: A population-based retrospective cohort study.
Matthes KL; Pestoni G; Korol D; Van Hemelrijck M; Rohrmann S
Urol Oncol; 2018 Jun; 36(6):309.e15-309.e23. PubMed ID: 29576269
[TBL] [Abstract][Full Text] [Related]
3. Impact of age and comorbidities on long-term survival of patients with high-risk prostate cancer treated with radical prostatectomy: a multi-institutional competing-risks analysis.
Briganti A; Spahn M; Joniau S; Gontero P; Bianchi M; Kneitz B; Chun FK; Sun M; Graefen M; Abdollah F; Marchioro G; Frohenberg D; Giona S; Frea B; Karakiewicz PI; Montorsi F; Van Poppel H; Jeffrey Karnes R;
Eur Urol; 2013 Apr; 63(4):693-701. PubMed ID: 22959192
[TBL] [Abstract][Full Text] [Related]
4. Impact of age, comorbidity, and PSA doubling time on long-term competing risks for mortality among men with non-metastatic castration-resistant prostate cancer.
Whitney CA; Howard LE; Freedland SJ; DeHoedt AM; Amling CL; Aronson WJ; Cooperberg MR; Kane CJ; Terris MK; Daskivich TJ
Prostate Cancer Prostatic Dis; 2019 May; 22(2):252-260. PubMed ID: 30279582
[TBL] [Abstract][Full Text] [Related]
5. Predicting prostate cancer-specific outcome after radical prostatectomy among men with very high-risk cT3b/4 PCa: a multi-institutional outcome study of 266 patients.
Moltzahn F; Karnes J; Gontero P; Kneitz B; Tombal B; Bader P; Briganti A; Montorsi F; Van Poppel H; Joniau S; Spahn M
Prostate Cancer Prostatic Dis; 2015 Mar; 18(1):31-7. PubMed ID: 25535100
[TBL] [Abstract][Full Text] [Related]
6. Impact of Charlson comorbidity index varies by age in patients with prostate cancer treated by radical prostatectomy: a competing risk regression analysis.
Lee JY; Lee DH; Cho NH; Rha KH; Choi YD; Hong SJ; Yang SC; Cho KS
Ann Surg Oncol; 2014 Feb; 21(2):677-83. PubMed ID: 24145996
[TBL] [Abstract][Full Text] [Related]
7. How socioeconomic and clinical factors impact prostate-cancer-specific and other-cause mortality in prostate cancer stratified by clinical stage: Competing-risk analysis.
He H; Han D; Xu F; Lyu J
Prostate; 2022 Mar; 82(4):415-424. PubMed ID: 34927741
[TBL] [Abstract][Full Text] [Related]
8. Age-adjusted Charlson comorbidity index is a significant prognostic factor for long-term survival of patients with high-risk prostate cancer after radical prostatectomy: a Bayesian model averaging approach.
Lee JY; Kang HW; Rha KH; Cho NH; Choi YD; Hong SJ; Cho KS
J Cancer Res Clin Oncol; 2016 Apr; 142(4):849-58. PubMed ID: 26660495
[TBL] [Abstract][Full Text] [Related]
9. Comorbidity and age cannot explain variation in life expectancy associated with treatment of non-metastatic prostate cancer.
Boehm K; Dell'Oglio P; Tian Z; Capitanio U; Chun FKH; Tilki D; Haferkamp A; Saad F; Montorsi F; Graefen M; Karakiewicz PI
World J Urol; 2017 Jul; 35(7):1031-1036. PubMed ID: 27796538
[TBL] [Abstract][Full Text] [Related]
10. Causes of death in men with prevalent diabetes and newly diagnosed high- versus favorable-risk prostate cancer.
D'Amico AV; Braccioforte MH; Moran BJ; Chen MH
Int J Radiat Oncol Biol Phys; 2010 Aug; 77(5):1329-37. PubMed ID: 19879061
[TBL] [Abstract][Full Text] [Related]
11. Weighted versus unweighted Charlson score to predict long-term other-cause mortality in men with early-stage prostate cancer.
Daskivich TJ; Kwan L; Dash A; Greenfield S; Litwin MS
Eur Urol; 2014 Dec; 66(6):1002-9. PubMed ID: 24924554
[TBL] [Abstract][Full Text] [Related]
12. Primary Treatment Choice Over Time and Relative Survival of Prostate Cancer Patients: Influence of Age, Grade, and Stage.
Matthes KL; Limam M; Dehler S; Korol D; Rohrmann S
Oncol Res Treat; 2017; 40(9):484-489. PubMed ID: 28813713
[TBL] [Abstract][Full Text] [Related]
13. Increased curative treatment is associated with decreased prostate cancer-specific and overall mortality in senior adults with high-risk prostate cancer; results from a national registry-based cohort study.
Aas K; Dorothea Fosså S; Åge Myklebust T; Møller B; Kvåle R; Vlatkovic L; Berge V
Cancer Med; 2020 Sep; 9(18):6646-6657. PubMed ID: 32750229
[TBL] [Abstract][Full Text] [Related]
14. Undertreatment of Men in Their Seventies with High-risk Nonmetastatic Prostate Cancer.
Bratt O; Folkvaljon Y; Hjälm Eriksson M; Akre O; Carlsson S; Drevin L; Franck Lissbrant I; Makarov D; Loeb S; Stattin P
Eur Urol; 2015 Jul; 68(1):53-8. PubMed ID: 25813688
[TBL] [Abstract][Full Text] [Related]
15. Differences according to socioeconomic status in the management and mortality in men with high risk prostate cancer.
Berglund A; Garmo H; Robinson D; Tishelman C; Holmberg L; Bratt O; Adolfsson J; Stattin P; Lambe M
Eur J Cancer; 2012 Jan; 48(1):75-84. PubMed ID: 21852113
[TBL] [Abstract][Full Text] [Related]
16. Influence of Comorbidity on the Risk of Mortality in Men With Unfavorable-Risk Prostate Cancer Undergoing High-Dose Radiation Therapy Alone.
Huynh MA; Chen MH; Wu J; Braccioforte MH; Moran BJ; D'Amico AV
Int J Radiat Oncol Biol Phys; 2016 Jul; 95(4):1158-67. PubMed ID: 27209511
[TBL] [Abstract][Full Text] [Related]
17. Association between type 2 diabetes, curative treatment and survival in men with intermediate- and high-risk localized prostate cancer.
Crawley D; Garmo H; Rudman S; Stattin P; Zethelius B; Holmberg L; Adolfsson J; Van Hemelrijck M
BJU Int; 2018 Feb; 121(2):209-216. PubMed ID: 28418195
[TBL] [Abstract][Full Text] [Related]
18. Causes of death in men with localized prostate cancer: a nationwide, population-based study.
Van Hemelrijck M; Folkvaljon Y; Adolfsson J; Akre O; Holmberg L; Garmo H; Stattin P
BJU Int; 2016 Mar; 117(3):507-14. PubMed ID: 25604807
[TBL] [Abstract][Full Text] [Related]
19. Current impact of age and comorbidity assessment on prostate cancer treatment choice and over/undertreatment risk.
Lunardi P; Ploussard G; Grosclaude P; Roumiguié M; Soulié M; Beauval JB; Malavaud B
World J Urol; 2017 Apr; 35(4):587-593. PubMed ID: 27443847
[TBL] [Abstract][Full Text] [Related]
20. Advancing age within established Gleason score categories and the risk of prostate cancer-specific mortality (PCSM).
Russo AL; Chen MH; Aizer AA; Hattangadi JA; D'Amico AV
BJU Int; 2012 Oct; 110(7):973-9. PubMed ID: 22954029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]